Objective:

To update the boxed warning for select menopausal hormone therapies based on a review of scientific literature.

Approach:

Key Findings:

• Removal of specific risk statements from the boxed warning for certain hormone therapies.
• Hormone therapy can significantly improve quality of life for menopausal women.
• Only about 2 million out of 41 million eligible women in the US received hormone therapy prescriptions in 2020.

Interpretation:

The FDA's decision aims to provide women with accurate information about the benefits of hormone therapy, potentially increasing its use among those who may benefit.

Limitations:

• The study does not address the reasons for low hormone therapy usage among eligible women.
• Long-term effects of the updated labeling on prescribing practices are yet to be evaluated.

Conclusion:

The FDA's approval of labeling changes for hormone therapies reflects a commitment to evidence-based medicine and aims to enhance women's health during menopause.

Sources:

• FDA
Source

Based on findings from:

FDA Approves HRT Label Changes

Kathryn Wighton. Conexiant, 2026.

https://conexiant.com/obgyn/articles/fda-approves-hrt-label-changes/

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.